Compare Diamondback Energy Inc (FANG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Zimmer Biomet Holdings Inc — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while Zimmer Biomet Holdings Inc trades at $89.46 (market cap $16.95B). The key difference: Diamondback Energy Inc is far larger — about 3.2× Zimmer Biomet Holdings Inc's market cap, and Diamondback Energy Inc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FANG | ZBH | |
|---|---|---|
Market Cap | $53.67B | $16.95B |
Volume | 2,250,644 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $213.69 | $103.98 |
52-Week Low | $137.29 | $79.58 |
Typical Hold Time | 69 Days | 89 Days |
Enterprise Value | $65.83B | $24.02B |
Dividend Yield | 2.3% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.30, up 4.3% today, showing strong momentum near its recent highs. The stock maintains a bullish technical outlook with solid fundamental support from growing revenue and consistent earnings beats. Recent Q2 2026 EPS of $6.48 exceeded expectations by 6.6%, while analyst consensus remains overwhelmingly positive with 90.6% buy ratings and a $231.77 price target. The company's cash flow generation remains robust with $8.76B from operations in 2025, supporting dividend payments and strategic investments.
FANG presents a compelling growth opportunity with strong Permian Basin positioning and improving operational efficiency, though investors should monitor oil price volatility and recent insider selling activity. The stock's current valuation at 36.5x P/E reflects growth expectations, while technical indicators suggest potential resistance near $195-$197 levels. With solid institutional support and positive industry outlook, FANG remains well-positioned for continued upside if execution remains strong.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
